NCT00701753终止不适用
A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses
TheraGenetics Limited1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2008年5月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 24
- 试验地点
- 1
研究概览
简要总结
An individual's genetic make-up is known to determine their response to antipsychotic medication. Genetic markers that determine efficacy and side effects of medication may be identified and used to predict treatment outcome.
The study is a naturalistic study of routinely prescribed antipsychotics using outcome measures undertaken as part of the routine clinical care of the cohort. These clinical data are linked with genetic information obtained from DNA and RNA from blood samples undertaken as part of the study.
No alteration is made to the subjects treatment regime or medication.
The study is a two stage investigation:
- The first stage involves the collection of a databank of clinical information and blood samples for DNA and RNA extraction from patients treated with antipsychotic medication.
- The second stage is a molecular genetic investigation of treatment-related genetic factors that may contribute to response prediction and predisposition to side effects.
From these genetic studies pharmacogenetic prediction tests will be validated and/or developed.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
入排标准
- 年龄范围
- 19 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent must be obtained
- •DSM-IV diagnosis must be one of:
- •schizophrenia
- •schizophreniform
- •schizoaffective
- •delusional disorder
- •brief reactive psychosis
- •psychosis not otherwise specified
- •Ethnic origin of both parents must be known
- •A minimum of 6 weeks continuous treatment completed with the given antipsychotic, prescribed at least at minimum recommended doses
- •Prospectively collected outcome data available (pre-treatment and after at least 6 weeks on treatment)
- •Exclusion criteria:
- •Significant psychiatric or medical co-morbidity including history of:
- •head injury with loss of consciousness
- •neurological disorder
- •mental retardation (DSM-IV)
- •drug or alcohol dependence (DSM-IV)
- •serious physical illness e.g. malignancy, hepatic/renal insufficiency
- •Concomitant psychotropic medication that may influence ratings
- •Concomitant antipsychotics, antidepressants or mood stabilisers prescribed for >2 weeks during the antipsychotic treatment period rated
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Pharmacogenetic Profiling of Antipsychotics-Induced X-Syndrome and Diabetes (PAXD)Metabolic SyndromeDiabetesNCT00201292National Health Research Institutes, Taiwan1,350
Unknown
不适用
Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With SchizophreniaSchizophreniaNCT02964923Xijing Hospital300
已完成
4 期
Antipsychotics and Gene Expression in Soft TissuesSchizophreniaDiabetesNCT01185743Medical University of Vienna16
进行中（未招募）
不适用
Effect of atypical antipsychotics on gene expression in soft tissues of healthy subjects. A placebo controlled randomised pilot study. - OLA_ZIPRAThe study will be conducted in 42 healthy volunteersEUCTR2009-011097-15-ATMedizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
已完成
4 期
Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) TreatmentMajor DepressionNCT03927950University of Tartu135